Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 995 across all filing types
Latest filing 2019-08-07 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Telix and GenesisCare Commence Prostate Cancer Study 3 pages 192.9KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing the commencement of a clinical study called ENHANCING by Telix Pharmaceuticals and GenesisCare. It describes the study's purpose, design, and potential clinical implications. There are no financial statements, regulatory filings, voting results, or management changes. The content focuses on clinical trial initiation and strategic partnership, which is typical of a Capital/Financing Update or a clinical development update. However, since it is about a clinical study commencement and not about fundraising or capital structure changes, it does not fit CAP. It is not a regulatory filing or report publication announcement. The document is an announcement of a clinical study start, which is best categorized under Regulatory Filings (RNS) as it does not fit any other specific category and is a general corporate announcement.
2019-08-07 English
ENHANCING Prostate Cancer Clinical Study - Investor Overview 10 pages 1.2MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about the ENHANCING Study, a Phase II clinical trial related to prostate cancer imaging and treatment. It includes study design, clinical background, scientific rationale, and commercialisation status. The content is structured as a presentation with slides, forward-looking statements, and scientific data. There is no indication that this is a formal regulatory filing, annual or interim financial report, earnings release, or legal proceeding. The document is clearly intended for investors or stakeholders to inform them about the study and its implications, which aligns with the characteristics of an Investor Presentation. The length (9473 characters) and the presence of multiple slides and detailed explanations support this classification. Therefore, the most appropriate filing type is Investor Presentation (IP).
2019-08-07 English
Collaboration with DKFZ for Image-Guided Prostate Surgery 3 pages 173.1KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing a collaboration and option agreement between Telix Pharmaceuticals and the German Cancer Research Center (DKFZ) for the development of a next-generation prostate imaging agent. It focuses on the strategic partnership, research plans, and potential commercial development of a new imaging technology. There are no financial statements, regulatory filings, voting results, or management changes discussed. The content is primarily an announcement of a business collaboration and option agreement, not a financial report, earnings release, or regulatory filing. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate news that does not fit other specific categories. Given the absence of financial data or formal report content, the most appropriate classification is Regulatory Filings (RNS).
2019-08-04 English
Telix and Merck Group Combination Therapy Collaboration 1
Regulatory Filings Classification · 95% confidence The document is a public announcement by Telix Pharmaceuticals Limited about entering into a research collaboration agreement with Merck Healthcare KGaA. It discloses the nature of the collaboration, the terms, and some background about the company. The document is relatively short (3161 characters) and does not contain any financial statements, detailed financial data, or regulatory filings such as annual or quarterly reports. It is a disclosure made under ASX Listing Rule 3.1, which typically requires companies to announce material information to the market. There is no indication that this is a full report, audit, earnings release, or management discussion. It is not a report publication announcement since it contains substantive information about the collaboration itself. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a material event (collaboration agreement) that does not fit into other specific categories like M&A, capital update, or earnings release.
2019-07-31 English
Lancet Publication Demonstrates Superiority of PSMA Imaging 2 pages 143.5KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the publication of a clinical study in Lancet Oncology comparing two imaging agents for prostate cancer. It discusses the study results, mentions regulatory interactions with the FDA and EU approval guidance, and provides background on the company and its products. There are no financial statements, earnings data, or detailed financial analysis. The document is not a report itself but an announcement of a scientific publication and regulatory updates. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings related to financial compliance. It is best classified as a Regulatory Filings (RNS) type because it is a general regulatory announcement and company update that does not fit other specific categories.
2019-07-31 English
Appendix 4C - June 2019 Quarter 5 pages 352.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed quarterly financial data including cash flow statements, payments to directors, financing facilities, estimated cash outflows for the next quarter, and compliance statements. It covers a specific quarter (June 2019) and includes substantive financial data and analysis for that period. The document is approximately 8,790 characters long, which is sufficient to be a full report rather than a brief announcement. The content aligns with a quarterly financial report rather than an annual report or earnings release. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q2 2019
2019-07-30 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.